Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dextrose infusion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males

NCT01514578
View directory record Official record
Conditions
Healthy
Interventions
TRV130A, Dextrose in Water
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
19 Years to 50 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 20, 2026, 8:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

NCT00924287
View directory record Official record
Conditions
Metastatic Cancer
Interventions
in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes

NCT04443153
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Personalized Feedback, Decision Support System, Sensor Augmented Mode
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon, Insulin
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 20, 2026, 8:08 AM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 20, 2026, 8:08 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 20, 2026, 8:08 AM EDT
Suspended Phase 4 Interventional

Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome

NCT01151176
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Regular Insulin
Drug
Lead sponsor
Universidade Positivo
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus

NCT00943787
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Hyperinsulinemic, euglycemic and hypoglycemic clamp
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 20, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Regulation of Endogenous Glucose Production by Central KATP Channels

NCT03540758
View directory record Official record
Conditions
Diabetes Mellitus, Glucose Metabolism Disorders
Interventions
Diazoxide, Nicotinic acid, Placebo
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Not applicable Interventional Results available

Inpatient Closed-loop Glucose Control

NCT01819844
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia
Interventions
Closed-loop blood glucose control
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 20, 2026, 8:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

NCT01319565
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 20, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

NCT03180307
View directory record Official record
Conditions
Ovarian Cancer
Interventions
OTL38, near infrared camera imaging system, laparotomy
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950
View directory record Official record
Conditions
Influenza
Interventions
2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 20, 2026, 8:08 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness

NCT00530023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Loma Linda, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

NCT00663169
View directory record Official record
Conditions
Arthritis, Gouty
Interventions
canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
Biological · Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Inpatient Setting

NCT01552603
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

NCT03834493
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Enzalutamide, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 20, 2026, 8:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427

NCT04475198
View directory record Official record
Conditions
Acute, Post-operative Pain
Interventions
ST-2427, Placebo
Drug
Lead sponsor
SiteOne Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 20, 2026, 8:08 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes

NCT00829062
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous glucose glucose sensor- physician ordered
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Sep 20, 2026, 8:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

NCT02592707
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Satoreotide tetraxetan, Amino acid solution, Antiemetic
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 20, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 20, 2026, 8:08 AM EDT